194 results on '"Timmers C"'
Search Results
2. Introduction of Small-Scale Biomass Gasification Systems in Rural China and the Amazon Region of Brazil
3. Data from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
4. Supplementary Figure 2 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
5. Supplementary Table 1 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
6. Supplementary Figure 1 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
7. Discovery of INCB123667, a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor for the treatment of cyclin E dysregulated cancers
8. Signaling of an allosteric, nanomolar potent, low molecular weight agonist for the follicle-stimulating hormone receptor
9. CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth
10. The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2
11. A signaling-selective, nanomolar potent allosteric low molecular weight agonist for the human luteinizing hormone receptor
12. 100 Spatial Transcriptomic Profiling Reveals Differential Cellular Dynamics in Atopic Dermatitis Skin Treated With Ruxolitinib Cream
13. Prevention of the Onset of Ovarian Hyperstimulation Syndrome (OHSS) in the Rat After Ovulation Induction with a Low Molecular Weight Agonist of the LH Receptor Compared with hCG and rec-LH
14. A Platform for the Generation of Site-Specific Antibody–Drug Conjugates That Allows for Selective Reduction of Engineered Cysteines
15. 220 (PB100) - Discovery of INCB123667, a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor for the treatment of cyclin E dysregulated cancers
16. Een collega toevoegen als vriend op Facebook : een verstandige keuze of toch maar niet?
17. Fluorescent small-molecule agonists as follicle-stimulating hormone receptor imaging tools
18. EXTH-83. TARGETING DNA REPAIR AND SURVIVAL PATHWAYS THROUGH HEAT SHOCK PROTEIN INHIBITION USING AT13387 TO SENSITIZE GLIOMA TO CHEMORADIATION THERAPY
19. A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer
20. Fanconi anemia D2 (fancd2) knockout mice have a phenotype more severe than fanca and fancc mice, but milder than brca1 mutants
21. A Mutation and Prognostic Biomarker Study in Grade II and III Gliomas Utilizing a Combined Cohort of NRG Oncology/RTOG 9802 and 9813
22. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
23. De prospectieve evaluatie van een zorgprogramma voor persoonlijkheidsstoornissen bij GGZ-MB
24. Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid-stimulating hormone receptor
25. A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers
26. Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985
27. Autismespectrumstoornis bij peuters: een stabiele diagnose?
28. Mouse development with a single E2F activator
29. De uitgever aan het woord 2006
30. 461 A phase I trial of dabrafenib (BRAF inhibitor) and pazopanib in BRAF mutated advanced malignancies
31. Genomic Characterization of Non-Small Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing
32. CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth
33. A Multi-Institutional Randomized Phase 2 Trial of the Oncolytic Virus Reolysin in the First Line Treatment Metastatic Adenocarcinoma of the Pancreas (Map)
34. Mouse development with a single E2F activator
35. Org 214007-0: A Novel Non-Steroidal Selective Glucocorticoid Receptor Modulator with Full Anti-Inflammatory Properties and Improved Therapeutic Index
36. Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid-stimulating hormone receptor
37. Contraception by induction of luteinized unruptured follicles with short-acting low molecular weight FSH receptor agonists in female animal models
38. Development of Selective LH Receptor Agonists by Heterodimerization with a FSH Receptor Antagonist
39. A note on the solid-phase synthesis of oligosaccharides by the Danishefski approach
40. ChemInform Abstract: An Alternative Route to the Preparation of (3′ → 5′) Methylene Acetal Linked Di- and Trinucleosides.
41. ChemInform Abstract: Rhodium(II)-Catalyzed Asymmetric Cyclopropanation of Glycals with Ethyl Diazoacetate.
42. ChemInform Abstract: Use of Furanoid Glycals in Oligosaccharide Synthesis.
43. ChemInform Abstract: Stereoselective Synthesis of α-C-(Alkynyl)-glycosides via Ring- Opening of α-1,2-Anhydrosugars.
44. ChemInform Abstract: A Study Towards Total Synthesis of Antibiotic Agrocin 84.
45. ChemInform Abstract: An Expeditious Route to Streptococci and Enterococci Glycolipids via Ring-Opening of 1,2-Anhydrosugars with Protic Acids.
46. Oligoproline helices as structurally defined scaffolds for oligomeric G protein-coupled receptor ligands
47. E2f1, E2f2, and E2f3 Control E2F Target Expression and Cellular Proliferation via a p53-Dependent Negative Feedback Loop
48. The β-glucuronyl-based prodrug strategy allows for its application on β-glucuronyl-platinum conjugates
49. LBA19 - A Multi-Institutional Randomized Phase 2 Trial of the Oncolytic Virus Reolysin in the First Line Treatment Metastatic Adenocarcinoma of the Pancreas (Map)
50. The First Orally Active Low Molecular Weight Agonists for the LH Receptor: Thienopyr(im)idines with Therapeutic Potential for Ovulation Induction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.